INTRODUCTION
============

The abnormal processing of cellular prion protein (PrP^C^) gives rise to PrP^SC^, or pathogenic prion, which is the etiologic agent of several transmissible spongiform encephalopathies (reviewed in [@B2]; [@B1]; [@B35]). These devastating encephalopathies are characterized by severe histological changes, including extensive neuronal death, reactive gliosis, and neuroinflammation, concomitant to the accumulation of the aggregated misfolded form of PrP^C^ in affected brains. Although necessary for prion propagation and infectivity ([@B73]), the repertoire of physiological roles of PrP^C^ remains to be fully determined. Indeed, PrP^C^ has been implicated in a wide range of neural functions, such as copper homeostasis ([@B11], [@B12]; [@B67]), neurotransmission ([@B37]; [@B47]; [@B50]), stem-cell proliferation and differentiation ([@B59]), malignant glioma proliferation ([@B21]), neurite outgrowth ([@B16]; [@B53]), and, more recently, putative cross-talk between neurodegenerative diseases ([@B32]; [@B24]; [@B25]).

Early in vitro studies with prion protein gene *Prnp^o/o^* mice (Zürich I) ([@B13]) showed that cultured *Prnp^o/o^* neurons were more prone to die than *Prnp^+/+^* neurons after serum withdrawal or other treatments ([@B31]). Subsequent studies ([@B10]; [@B48]; [@B5]) indicated that PrP^C^ might play a neuroprotective function in the context of excitotoxic lesions. Indeed, it was demonstrated in rats that *Prnp* is overexpressed in ischemic brains and protects cortical neurons after ischemia ([@B39]; [@B56]; [@B57]; [@B72]; [@B41]). In fact, cells overexpressing PrP^C^ show increased toxicity after endoplasmic reticulum stress ([@B4]). Neuroprotective effects of PrP^C^ after central nervous system insults have been associated with both extracellular and intracellular effectors (e.g., the stress-induced-phosphoprotein 1) ([@B77]) and are mediated by PI3K-mTOR signaling ([@B38]; [@B51]). However, although it is involved in Alzheimer\'s disease ([@B32]), PrP^C^ does not act as a major modulator in a panel of neurodegenerative disease models ([@B60]).

In neurons, PrP^C^ has been localized in axons at the synapse ([@B23]; [@B22]), which might be consistent with reports of deficits in neurotransmission in *Prnp* knockout mice ([@B37], [@B36]; [@B29]; [@B47]; [@B50]). Indeed, PrP^C^ knockout mice are more prone to cell death after kainate (KA) injections than are *Prnp^+/+^* animals ([@B70]; [@B49], [@B50]). In addition, *Prnp^o/o^* neurons are also highly susceptible to acute *N*-methyl-[d]{.smallcaps}-aspartic acid (NMDA) or KA treatment in hippocampal slices ([@B49]; [@B29]). These findings suggest that PrP^C^ can modulate signaling cascades by activating stress-protective pathways, or by inhibiting cytotoxic pathways (reviewed in [@B74]; [@B44]). Although the exact mechanism(s) are unknown, the neuroprotective function may be associated with differential expression of glutamate receptor subunits or the modulation of ligand/receptor affinities ([@B37]; [@B29]; [@B50]). In particular, it remains to be established whether PrP^C^ alters KA receptor--mediated neurotransmission at the neuron membrane. In fact, PrP^C^-binding proteins include, among others, membrane receptors ([@B52]), and two recent studies reported cell-specific effects of glutamate and the role of PrP^C^ in these processes. Indeed, group I metabotropic glutamate receptors are involved in the transduction of cellular signals triggered by PrP^C^, which modulates neurite outgrowth ([@B7]). In addition, in NMDA-mediated toxicity, the protective role of PrP^C^ is mediated by the silencing of NMDA receptors containing *N*-methyl-[d]{.smallcaps}-aspartate receptor subtype 2 (NR2D) subunits ([@B29]).

In a previous study, we reported the increased presence of phosphorylated c-Jun N-terminal kinase 3 (JNK) in dying pyramidal neurons in the CA1 of the hippocampus of *Prnp* knockout mice after KA treatment ([@B49]). Here we show that KA-induced excitotoxicity in *Prnp* knockout mice depends on JNK3 activity, by developing a double-knockout mouse lacking PrP^C^ and JNK3 expression and analyzing it by using gene expression and pharmacological approaches. Furthermore, we propose a mechanism by which PrP^C^ regulates the KA receptor function through interaction, at the postsynaptic level, with the glutamate receptor 6/7 (GluR6/7) and the postsynaptic density 95 protein (PSD-95), which in turn modulates JNK3 activity.

RESULTS
=======

Enhanced susceptibility to KA-induced seizures in *Prnp* knockout mice and its reversion in *Prnp^o/o^Jnk3^o/o^* mice
---------------------------------------------------------------------------------------------------------------------

The thresholds for onset of seizure behavior in response to identical intraperitoneal KA injections (6 mg/kg body weight) in the four mouse genotypes *Prnp^o/o^Jnk3^+/+^, Prnp^+/+^Jnk3^o/o^, Prnp^+/+^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* were analyzed. After the first KA injection, *Prnp^o/o^Jnk3^+/+^* animals developed profound hypoactivity and immobility (grades I--II). After successive injections, hyperactivity (grade III) and scratching (grade IV) were often observed. Some mice progressed to a loss of balance control (grade V) and further chronic whole-body convulsions (grade VI). The bouncing activity commonly referred to as "popcorn" behavior was included in grade VI. After the behavioral study, mice were numbered and kept in separate boxes until histological or biochemical studies; see later discussion. Twelve hours after KA treatment, *Prnp^+/+^Jnk3^+/+^* and *Prnp^+/+^Jnk3^o/o^* animals showed normal behavior. KA-treated *Prnp^o/o^Jnk3^o/o^* mice displayed hypoactivity, immobility, and sensitivity to external stimuli (e.g., box handling) ([Table 1](#T1){ref-type="table"}).

###### 

Effect of KA-induced status epilepticus and death in *Prnp^+/+^Jnk3^+/+^*, *Prnp^o/o^Jnk3^+/+^*, *Prnp^o/o^Jnk3^o/o^*, and *Prnp^+/+^Jnk3^o/o^* mice.

  Genotype.              Animal   Number of seizures   Number of blinkings   Behavioral stages   Prioritary stage
  ---------------------- -------- -------------------- --------------------- ------------------- ------------------
  *Prnp^+/+^Jnk3^+/+^*   1        1                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   2        0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   3        1                    1                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   4        1                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   5        0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   6        0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   7        0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   8        0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   9        0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   10       1                    0                     I--III              II
  *Prnp^+/+^Jnk3^+/+^*   11       0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   12       0                    0                     I--II               II
  *Prnp^o/o^Jnk3^+/+^*   13       8                    4                     I--VI               †
  *Prnp^o/o^Jnk3^+/+^*   14       5                    3                     I--VI               IV--VI
  *Prnp^o/o^Jnk3^+/+^*   15       6                    4                     I--VI               V--VI
  *Prnp^o/o^Jnk3^+/+^*   16       6                    3                     I--VI               †
  *Prnp^o/o^Jnk3^+/+^*   17       5                    2                     I--VI               V--VI
  *Prnp^o/o^Jnk3^+/+^*   18       6                    3                     I--VI               †
  *Prnp^o/o^Jnk3^+/+^*   19       6                    4                     I--VI               V--VI
  *Prnp^o/o^Jnk3^+/+^*   20       5                    2                     I--VI               IV--VI
  *Prnp^o/o^Jnk3^+/+^*   21       4                    2                     I--VI               V--VI
  *Prnp^o/o^Jnk3^+/+^*   22       8                    5                     I--VI               V--VI
  *Prnp^o/o^Jnk3^+/+^*   23       6                    3                     I--VI               IV--VI
  *Prnp^o/o^Jnk3^+/+^*   24       7                    5                     I--VI               V--VI
  *Prnp^o/o^Jnk3^o/o^*   25       1                    1                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   26       2                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   27       1                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   28       0                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   29       0                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   30       0                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   31       0                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   32       2                    2                     I--III              II
  *Prnp^o/o^Jnk3^o/o^*   33       0                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   34       1                    1                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   35       0                    0                     I--II               II
  *Prnp^o/o^Jnk3^o/o^*   36       0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   37       0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   38       0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   39       0                    0                     I--II               II
  *Prnp^+/+^Jnk3^+/+^*   40       0                    0                     I--II               II

See *Results* for stage classification.

*Prnp^o/o^Jnk3^+/+^* mice were highly susceptible to KA, showing a greater number (from five to eight) of severe seizures (grade VI). In addition, they maintained grade IV--VI seizures for 2--3 h after the first episode, whereas and *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^o/o^* mice displayed only grade III seizure. Furthermore, three *Prnp^o/o^Jnk3^+/+^* animals died during the experiments. These data corroborate previous results ([@B70]; [@B49], [@B50]) indicating increased sensitivity to KA in *Prnp* knockout mice. We established that the minimal concentration of KA required to induce seizures in the *Prnp^+/+^Jnk3^+/+^* animals was 35--40 mg/kg body weight, which is similar to that required for *Prnp^+/+^Jnk3^+/o^.* At this concentration, all *Prnp^o/o^Jnk3^+/+^* animals died shortly after a second injection. These results suggested an active role of JNK3 in *Prnp^o/o^* susceptibility to KA. Indeed, *Prnp*^+/+^*Jnk3^o/o^* and *Prnp^+/+^Jnk3^+/o^* mice were not affected by KA treatment as described ([@B76]).

Decreased seizures in *Prnp^o/o^Jnk3^o/o^* mice correlated with lower number of dying cells in the hippocampus
--------------------------------------------------------------------------------------------------------------

Protein expression was analyzed by Western blot ([Figure 1A](#F1){ref-type="fig"}), which showed that PrP^C^ expression was similar in *Prnp^+/+^Jnk3^+/+^* and *Prnp*^+/+^*Jnk3^o/o^* mice. In addition, JNK3 expression was similar in *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^+/+^* mice, and neither of these proteins was detected in the double-knockout mice, as expected ([Figure 1A](#F1){ref-type="fig"}). Next we analyzed in more detail the time course of the seizure score after KA injection ([Figure 1B](#F1){ref-type="fig"}). *Prnp^o/o^Jnk3^+/+^* mice showed maximum scores (V--VI) between 90 and 180 min after the first KA injection. To determine whether the severity of seizure observed in *Prnp^o/o^Jnk3^+/+^* correlates with neuronal loss and reactive glial changes in the hippocampus after KA injection, we carried out several histochemical and immunohistochemical analyses ([Figure 1, C and D](#F1){ref-type="fig"}).

![KA-dependent sensitivity, seizure behavior, neurotoxicity and apoptosis in the different genotypes studied. (A) Western blot of JNK3, PrP^C^, and tubulin in protein extract from the hippocampi of the different mouse strains used in this study (*Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^, Prnp^o/o^Jnk3^o/o^*, and *Prnp^+/+^Jnk3^o/o^*); tubulin was used as a loading control. (B) Comparison of seizure responses in littermates of *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^, Prnp^o/o^Jnk3^o/o^*, and *Prnp^+/+^Jnk3^o/o^* mice to intraperitoneal injection of KA (6 mg/kg body weight) or 0.1 M PBS. KA-injection timing is indicated below the graph. Seizures were scored as indicated in *Materials and Methods*. Eight mice in each group were observed and scored to determinate the time-dependent seizure score. (C) Photomicrographs showing examples of the pattern of Fluoro-Jade B and DAPI staining of hippocampal region of *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice after 24 h of KA treatment. Dying cells positive for Fluoro-Jade B are located in the pyramidal cell layer of *Prnp^o/o^Jnk3^+/+^* (arrows). (D) Examples of TUNEL-positive cells in CA1--CA3 hippocampal regions of *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice after 24 h of KA treatment. (E) Quantification of Fluoro-Jade B and TUNEL-positive cells in the CA1 and CA3 regions of the hippocampus in *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice after 24 h of KA treatment. Results are obtained from nine mice per genotype. DG, dentate gyrus; CA1--3, hippocampal regions 1 and 3; gl, granule cell layer; h, hilus; ml, molecular layer; sl, stratum lucidum; slm, stratum lacunosum-moleculare; so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. Scale bar, C, top, 200 μm; C, bottom, 100 μm; D, 100 μm. Asterisks in E indicate statistical significance (\*\*\*p \< 0.001, ANOVA test).](3041fig1){#F1}

First, we analyzed the pattern of neurodegeneration in the *Prnp^+/+^Jnk3^+/+^*, *Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice 24 h after KA treatment by using Fluoro-Jade B staining ([@B55]; [Figure 1C](#F1){ref-type="fig"}). Numerous Fluoro-Jade B--positive pyramidal neurons were observed in the CA1 and CA3 regions of *Prnp^o/o^Jnk3^+/+^* hippocampus. In the other genotypes Fluoro-Jade B labeling was rare and generally pale ([Figure 1C](#F1){ref-type="fig"}). To further corroborate the death of these neurons, we applied in parallel sections the in situ nick-translation technique with biotinylated-UTP to determine the DNA fragmentation level (TUNEL technique, by using ApopTag kit; [@B26]; [Figure 1D](#F1){ref-type="fig"}). Distribution of TUNEL-positive nuclei largely correlated with the pattern of Fluoro-Jade B labeling observed in the CA1 and CA3 of *Prnp^o/o^Jnk3^+/+^* mice ([Figure 1, D and E](#F1){ref-type="fig"}). Cell counts showed statistical significance (see *Materials and Methods* for details) when comparing data of *Prnp^o/o^Jnk3^+/+^* mice with any of the other two genotypes.

Acute down-regulation of PrP^C^ expression in *Prnp^+/+^Jnk3^+/+^* primary neuronal cultures increased susceptibility to KA
---------------------------------------------------------------------------------------------------------------------------

We examined whether the neurotoxic effects of KA are modified when PrP^C^ expression levels are acutely altered in *Prnp^+/+^Jnk3^+/+^* neurons. Thus, *Prnp^+/+^Jnk3^+/+^* primary cortical neurons were infected with a lentivirus carrying a small interfering RNA (siRNA) interference sequence for *Prnp*. Cells infected with lentivirus showed an 81% decrease in PrP^C^ expression ([Figure 2A](#F2){ref-type="fig"}). After exposure to KA, cells infected with lentivirus showed a statistically significant 29% decrease in survival ([Figure 2B](#F2){ref-type="fig"}) compared with parallel enhanced green fluorescent protein (eGFP)--infected cultures ([Figure 2B](#F2){ref-type="fig"}). Thus, although similar data were previously described in neuroblastoma cells (N~2~A) using interference RNA against *Prnp* ([@B49]), this is the first observation of KA-mediated cell death after acute PrP^C^ down-regulation in *Prnp^+/+^Jnk3^+/+^* neurons. This finding reinforces the notion that decreased expression of PrP^C^ compromises neuronal viability after acute KA treatment.

![Decrease in PrP^C^ expression--enhanced KA neurotoxicity in primary hippocampal neurons. Primary hippocampal neurons were infected with lentivirus containing eGFP or siRNA for *Prnp* for 24 h. Next, neurons were treated with 150 μM KA for 8 h, and cell viability was analyzed after further 24 h with the WST-1 method as indicated in *Materials and Methods*. (A) Western blot for PrP^C^ and tubulin expression after lentiviral infection with eGFP and siRNA *Prnp*. Note the decrease of the PrP^C^ expression after lentiviral infection vs. vehicle and eGFP. (B) Histogram illustrating cell viability infection and KA exposure. No differences were observed between vehicle and eGFP. Data are expressed as fold increase ± SEM of three independent experiments. Asterisks in B indicate statistical significance (\*\*p \< 0.01, ANOVA test).](3041fig2){#F2}

Differential activation of JNK3 and extracellular regulated kinases 1/2 in *Prnp^o/o^Jnk3^+/+^* mouse hippocampus treated with KA
---------------------------------------------------------------------------------------------------------------------------------

Because genetic deletion of *Jnk3* on a *Prnp^o/o^* background overcomes the intrinsic susceptibility to KA of PrP^C^-deficient mice, we next developed several experiments to identify changes in JNK3 activation in the hippocampus after KA treatment ([Figure 3](#F3){ref-type="fig"}). Mice were injected with KA as described and killed 6 h later (see *Materials and Methods* for details). Activation of extracellular regulated kinase (ERK) 1/2, JNK3, c-Jun, and p53 was analyzed in protein samples from the hippocampus of treated mice by Western blot and compared with vehicle-injected mice. In the absence of KA, ERK1/2 was activated in *Prnp^o/o^Jnk3^+/+^* and *Prnp^o/o^Jnk3^o/o^* hippocampus compared with *Prnp^+/+^Jnk3^+/+^* mice ([Figure 3A](#F3){ref-type="fig"}). These data corroborate the reported data of ERK1/2 activation in *Prnp* knockout mice ([@B10]). In parallel to the phosphorylation of ERK1/2 in all genotypes after KA treatment, an increase in p-JNK3 and p-c-Jun Ser^63^ was observed in *Prnp^o/o^Jnk3^+/+^* hippocampus ([Figure 3A](#F3){ref-type="fig"}). This phosphorylation was undetectable in vehicle-treated mice and in *Prnp^+/+^Jnk3^+/+^*, as well as in *Prnp^o/o^Jnk3^o/o^* mice ([Figure 3A](#F3){ref-type="fig"}) and *Prnp^+/+^Jnk3^o/o^* (unpublished data), as expected. Total c-Jun protein was slightly increased in *Prnp^+/+^Jnk3^+/+^* but strongly increased in both *Prnp^o/o^Jnk3^+/+^* and *Prnp^o/o^Jnk3^o/o^* after KA treatment ([Figure 3A](#F3){ref-type="fig"}). Finally, p53, which was recently reported to be activated in a JNK-dependent manner in dying hippocampal neurons after glutamate and/or KA ([@B18]), was phosphorylated at Ser-15 and activated in *Prnp^o/o^Jnk3^+/+^* hippocampus after KA treatment.

![KA-induced neurotoxicity in *Prnp* knockout hippocampal mouse correlates with JNK3 activation. (A) Western blot for p-JNK, JNK3, p-ERK1/2, ERK1/2, p-c-Jun, c-Jun, p-p53, and tubulin from hippocampus extracts of *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice after 6 h of KA treatment (6 mg/kg body weight). KA-induced neurotoxicity in the *Prnp^o/o^Jnk3^+/+^* hippocampus is cell-specific and dependent on JNK3 activity. (B) Photomicrograph illustrating the pattern of p-ERK1/2 in the different phenotypes after 24 h of KA treatment. Notice the relevant increase of p-ERK1/2 in *Prnp^o/o^Jnk3^+/+^* and *Prnp^o/o^Jnk3^o/o^* hippocampus. (C) High magnification of the CA1 region of hippocampus from *Prnp^o/o^Jnk3^+/+^,* after 24 h of KA treatment, immunostained with p-ERK1/2 and GFAP antibodies. Note that numerous cells are double labeled (arrows). (D) Photomicrograph illustrating examples of the CA1 region of the three genotypes analyzed after 24 h of KA treatment and immunostained for GFAP. Levels of reactive glia are not completely abolished by the genetic deletion of *Jnk3*. Abbreviations as in [Figure 1](#F1){ref-type="fig"}. Scale bars, B, 150 μm; C, 100 μm; and D, 100 μm.](3041fig3){#F3}

These results suggest that signaling pathways other than the JNK3 pathway are activated after KA treatment. Indeed, we determined the cellular expression of ERK1/2 in detail in treated mice ([Figure 3, B and C](#F3){ref-type="fig"}). p-ERK1/2 staining was strong in hippocampal mossy fibers at the *stratum lucidum* in *Prnp^o/o^Jnk3^+/+^ and Prnp^o/o^Jnk3^o/o^*, with low levels in *Prnp^+/+^Jnk3^+/+^*, after 24 h of KA treatment. Double-labeling techniques with glial fibrillary acidic protein (GFAP) and p-ERK1/2 revealed a second group on p-ERK1/2--stained cells at CA1 and CA3 regions ([Figure 3C](#F3){ref-type="fig"}). However, detailed observation of astroglial cells in these mutants revealed an increased reactivity of astrocytes in *Prnp^o/o^Jnk3^+/+^* hippocampus (relevant GFAP content and thick glial expansions), in contrast to moderate reactivity in *Prnp^o/o^Jnk3^o/o^* and absence in *Prnp^+/+^Jnk3^+/+^* mice ([Figure 3D](#F3){ref-type="fig"}). Thus these data indicate that most p-ERK1/2 staining observed in *Prnp^o/o^Jnk3^+/+^* and *Prnp^o/o^Jnk3^o/o^* after KA treatment is mainly associated with mossy fiber staining with the participation of GFAP-reactive cells.

The JNK3 pathway is implicated in *c-fos* and *c-jun* activation after glutamate treatment ([@B9]). To discriminate the particular contribution of JNK3 to *c-jun* and *c-fos* expression in our experiments, we performed quantitative real-time PCR (RT-qPCR; [Figure 4](#F4){ref-type="fig"}). Data obtained demonstrate that both *c-jun* and *c-fos* were overexpressed in the hippocampus of *Prnp^o/o^Jnk3^+/+^* mice 6 h after KA administration (4.10- and 49.2-fold increase, respectively; [Figure 4A](#F4){ref-type="fig"}). Deletion of *Jnk3* in *Prnp^o/o^* mice offset the *c-jun* and *c-fos* increase by 34 and 25% respectively, compared with *Prnp^o/o^Jnk3^+/+^* levels. These results support the idea that other KA-activated pathways are the main contributors to the overexpression of both early genes. To examine this hypothesis, we analyzed the differential expression of cyclooxygenase-2 (*cox-2*), a molecular target of JNK activation in neurodegeneration and inflammation activated by activator protein-1 (AP-1; [@B28]). RT-qPCR of *cox-2* revealed statistically significant overexpression in the *Prnp^o/o^Jnk3^+/+^* hippocampus after KA treatment. Furthermore, stronger decrease of *cox-2* was observed in *Prnp^o/o^Jnk3^o/o^* (60% compared with those reported by *c-jun* and *c-fos*) ([Figure 4B](#F4){ref-type="fig"}). The results indicate that the absence of *Jnk3* is not the only factor mediating the early changes in gene expression mediated by KA.

![RT-qPCR of (A) *c-jun* and *c-fos* and (B) *cox-2* from hippocampal RNA extracts of *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice treated with KA (6 mg/kg body weight) or buffer for 6 h. Data (mean ± SEM) represent mean fold induction obtained in three independent experiments. GAPDH was used as the housekeeping gene. Data are referred with *Prnp^+/+^Jnk3^+/+^* in each histogram in the absence or presence of KA. Data are expressed as fold change ± SEM. Asterisks in A and B indicate statistical significance (\*\* p \< 0.01, \*\*\* p \< 0.001, ANOVA test).](3041fig4){#F4}

Pharmacological inhibition of JNK in *Prnp^o/o^Jnk3^+/+^* hippocampal slices overcame the neurotoxic effect of KA
-----------------------------------------------------------------------------------------------------------------

To ascertain whether neurotoxic differences are cell specific or associated with an increased glutamatergic input from the entorhinal cortex, we performed a parallel study in isolated hippocampal slices ([Figure 5](#F5){ref-type="fig"}). *Prnp^o/o^Jnk3^+/+^* and *Prnp^+/+^Jnk3^+/+^* hippocampal slices were treated with KA or phosphate-buffered saline (PBS), following the addition (when indicated) of two different JNK inhibitors: the pharmacological inhibitor SP600125 and the peptide TAT-JIP, a specific inhibitor derived from the minimal JNK-binding region of the scaffold protein JNK-interacting protein 1 (JIP-1) coupled to the short cell-permeable TAT sequence ([@B8]; [Figure 5A](#F5){ref-type="fig"}). After propidium iodide (PI) incubation, we observed few randomly distributed, labeled cells in the CA1--CA3 of *Prnp^+/+^Jnk3^+/+^--*derived hippocampal slices. However, *Prnp^o/o^Jnk3^+/+^* slices showed a statistically significant 71% increase of PI fluorescence compared to *Prnp^+/+^Jnk3^+/+^* cultures ([Figure 5B](#F5){ref-type="fig"}). The inhibition of JNK activity with SP600125 and TAT-JIP in *Prnp^o/o^Jnk3^+/+^*--derived slices decreased the fluorescence levels by 54 and 42%, respectively, compared with parallel KA-treated slices without the inhibitors ([Figure 5, B and C](#F5){ref-type="fig"}). These data indicate that increased cell death of hippocampal *Prnp^o/o^Jnk3^+/+^* neurons is associated with intrinsic synaptic properties.

![KA-enhanced neurotoxicity in *Prnp* knockout organotypic slices correlates with JNK3 activation. (A) Schematic diagram illustrating the experimental procedure. The hippocampi of *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^+/+^* animals were dissected and cultured in transwells until drug treatment and afterward analyzed by PI uptake. (B) Examples of PI uptake in organotypic hippocampal slice cultures from *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^+/+^* mice treated with 0.1 M PBS or 150 μM KA for 2 h in the presence or absence of JNK inhibitors SP600125 (20 μM) and TAT-JIP (10 μM) as indicated. Twenty-four hours after treatment slices were incubated with PI. Note the incorporation of PI in dying cells in KA-treated slices from *Prnp^o/o^Jnk3^+/+^* mice. (C) Histogram illustrating quantitative results of A. Histograms represent the mean ± SEM of three independent experiments. Asterisks in C indicate statistical significance (\*\*\*p \< 0.001, ANOVA test). Abbreviations as in [Figure 1](#F1){ref-type="fig"}. Scale bars, B, 100 μm.](3041fig5){#F5}

Coimmunoprecipitation of PrP^C^ with PSD-95 and GluR6/7 in the PSD fractions
----------------------------------------------------------------------------

To investigate the participation of PrP^C^ in the neurotoxic effects of KA, we examined whether PrP^C^ exerts its neuroprotective function by modulating the intracellular signaling triggered by KA receptor after ligand binding. Because neuronal depolarization mediated by KA requires the interaction of the GluR6/7 subunit of KA receptor with PSD-95 and MLK3 to form a trimeric complex ([@B45]; [@B34]), we analyzed biochemically the distribution of GluR6/7 and PrP^C^ in the *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* hippo­campus and whether changes in JNK3 alter the normal distribution of PrP^C^. Enriched PSD fractions were isolated from the hippocampus of *Prnp^+/+^Jnk3^+/+^*, *Prnp^o/o^Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice 6 h after administration of KA and processed for GluR6/7, PSD-95, and PrP^C^ by Western blot ([Figure 6A](#F6){ref-type="fig"}). Correct purification of the PSD fractions was corroborated since the percentage of PSD-95 in this fraction was 91.6% of total PSD-95. Results revealed no changes in subcellular distribution of these proteins among genotypes. As expected, PrP^C^ was detected in all cell compartments but enriched in PSD fractions, where GluR6/7 and PSD-95 were also found.

![PrP^C^ interacts with PSD-95 and glutamate receptor 6/7. (A) Hippocampus from KA-injected *Prnp^+/+^Jnk3^+/+^, Prnp^o/o^ Jnk3^+/+^*, and *Prnp^o/o^Jnk3^o/o^* mice was fractionated by differential centrifugation in order to purify PSD fraction. Fractions were separated by SDS--PAGE, followed by immunoblotting with the indicated antibodies. (B) Extracts from total hippocampus or hippocampal PSD fraction from *Prnp^+/+^Jnk3^+/+^* mouse were immunoprecipitated using two PrP^C^ antibodies (6H4 and SAF61). Immunoprecipitated samples were separated by SDS--PAGE, followed by immunoblotting with the indicated antibodies. (C) *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^+/+^* mice were injected with KA (6 mg/kg body weight) or PBS and analyzed for 4 h. Hippocampi were dissected, and cellular extracts were immunoprecipitated with control and anti--PSD-95 antibodies. Immunoprecipitated samples were developed by Western blot with the anti--GluR6/7 antibody. Densitometry values are standardized with *Prnp^+/+^Jnk3^+/+^* in untreated cultures, and quantification was represented as fold change ± SEM. Notice the increase of GluR6/7 labeling after PSD immunoprecipitation in *Prnp^o/o^Jnk3^+/+^* after KA treatment.](3041fig6){#F6}

These results suggested a putative interaction between GluR6/7 and PrP^C^. To explore this possibility, we performed coimmunoprecipitation experiments from whole *Prnp^+/+^Jnk3^+/+^* hippocampus protein extracts and PSD fractions using two different PrP^C^ antibodies (6H4 and SAF61; see *Materials and Methods*; [Figure 6B](#F6){ref-type="fig"}). Results indicated that PrP^C^ interacts with PSD-95 and GluR6/7 both in whole-hippocampus extracts and in purified PSD. As expected, both interactions were stronger in the PSD fraction ([Figure 6B](#F6){ref-type="fig"}). Taken together, these results implicate PrP^C^ in the binding of PSD-95 with the KA receptor containing GluR6/7. This would allow the formation of the ternary complex (GluR6/7--PSD-95--MLK3), which in turn activates the JNK3 pathway. Thus, to determine this, we immunoprecipitated PSD-95 in hippocampal protein extracts from *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^+/+^* mice to measure the amount of GluR6/7 coimmunoprecipitated in the presence or absence of KA ([Figure 6C](#F6){ref-type="fig"}). Immunoblots showed that the interaction between GluR6/7 and PSD-95 was higher in the hippocampus of *Prnp^o/o^Jnk3^+/+^* compared with *Prnp^+/+^Jnk3^+/+^* mice in the presence of KA (1.01 vs. 2.13, respectively; [Figure 6C](#F6){ref-type="fig"}). Taken together, these data indicate that, in the absence of PrP^C^, KA treatment increased the binding of GluR6/7-containing KA receptors to PSD-95, which correlates with increased activation of JNK3.

Increased KA-mediated neurotoxicity in *Prnp^o/o^* mice was reversed by 6,7-dinitroquinoxaline-2,3-dione and NS-102
-------------------------------------------------------------------------------------------------------------------

To examine the role of GluR6/7 in KA-induced neurotoxicity in *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^+/+^* mice, we injected the AMPA/KA inhibitor 6,7-dinitroquinoxaline-2,3-dione (DNQX) and the GluR6 antagonist NS-102 ([@B68]) prior to the intraperitoneal injection with KA ([Figure 7](#F7){ref-type="fig"}). DNQX inhibits AMPA/KA receptors in vivo ([@B3]) and inhibits JNK3 activation after excitotoxic insults ([@B64]), and NS-102 is a good functional antagonist of GluR6 *in vivo* in response to excitotoxic insults ([@B64]; [@B27]; [@B15]). First, we counted the seizures and the blinking episodes in treated mice ([Figure 7A](#F7){ref-type="fig"}). Pharmacological treatments indicate that preinjection with DNQX and, more effectively, with NS-102 reduced the number of all of the episodes counted in *Prnp^o/o^Jnk3^+/+^* mice. *Prnp^+/+^Jnk3^+/+^* mice were almost insensitive to KA, as described earlier ([Figure 7A](#F7){ref-type="fig"}). Again, both treatments reduced the number of Fluoro-Jade B--positive cells in the hippocampus ([Figure 7B](#F7){ref-type="fig"}) and the presence of p-c-Jun in *Prnp^o/o^Jnk3^+/+^* hippocampus in Western blots ([Figure 7C](#F7){ref-type="fig"}). In addition, we examined the effect of DNQX and NS-102 on c-Fos expression, which was overexpressed in the hippocampus of *Prnp^o/o^Jnk3^+/+^* mice after KA injections (see earlier discussion). Blockage of both AMPA/KA receptors and GluR6 prevented c-Fos overexpression in CA1 ([Figure 7D](#F7){ref-type="fig"}) and increased immunostaining of p-ERK1/2 in mossy fibers of *Prnp^o/o^Jnk3^+/+^* ([Figure 7E](#F7){ref-type="fig"}). Measure of the fluorescence in the mossy fibers with ImageJ software (square regions of interest of 75 × 75 μm, six measures per section) indicates a statistically significant reduction of 80 and 75% of p-ERK1/2 staining after DNQX and NS-102 treatments respective ([Figure 7F](#F7){ref-type="fig"}).

![AMPA/kainate receptor inhibition decreased the KA-enhanced neurotoxicity in *Prnp^o/o^Jnk3^+/+^* mice. (A) Seizures and blinking events for KA-injected mice. Injections were carried out with KA (6 mg/kg body weight), PBS, and the inhibitors DNQX and NS-102 as indicated on the timeline. (B) Examples of Fluoro-Jade B and DAPI staining in hippocampal CA1 region of *Prnp^o/o^Jnk3^+/+^* mice 24 h after injection of KA in the presence or absence of DNQX and NS-102. (C) Western blots of p-c-Jun, c-Jun, and tubulin from the hippocampus of the animals 4 h after injection of KA in presence or absence of DNQX and NS-102. (D) Photomicrographs of c-Fos immunoreactivity in the hippocampal CA1 region of *Prnp^o/o^Jnk3^+/+^* mice 24 h after injection of KA in the presence or absence of DNQX and NS-102. (E) Photomicrographs of p-ERK1/2 immunoreactivity in the hippocampus of *Prnp^o/o^Jnk3^+/+^* mice 24 h after injection of KA in the presence or absence of DNQX and NS-102. Representative images from three different experiments are shown. (F) Histogram illustrating quantitative results of the fluorescence levels analyzed in E. Data are represented as mean ± SEM. Asterisks indicate statistical significance (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; ANOVA test). Abbreviations as in [Figure 1](#F1){ref-type="fig"}. Scale bars, B, 100 μm; E, 200 μm.](3041fig7){#F7}

DISCUSSION
==========

Differential participation of ERK1/2, JNK3 kinases, and early gene expression in KA-mediated neuronal death in *Prnp^o/o^* mice
-------------------------------------------------------------------------------------------------------------------------------

In this study we demonstrate that abolition of JNK3 activity (either genetically or pharmacologically) blocks the neurotoxic activity induced by KA in *Prnp^o/o^* mice. These data indicate that the signal for neuronal cell death in *Prnp* knockout mice is mainly associated with JNK3 activity. In addition, to avoid the effects of the increased oxidative phenotype in absence of *Prnp* ([@B75]; [@B10]), we show that an acute decrease in PrP^C^ expression in cultured neurons from *Prnp^+/+^Jnk3^+/+^* mice also increased their susceptibility to KA. In fact, absence of *Jnk3* completely blocked the epileptogenic effects of KA in *Prnp^+/+^* mice, and the original *Jnk3^o/o^* mice were characterized as being resistant to KA, with similar scores to those reported here ([@B76]; [@B19]).

Although basal p-ERK1/2 is higher in *Prnp^o/o^* mice ([@B10]; [@B17]; [@B43]; [@B49]; and present results), treatment with KA induces overphosphorylation of ERK1/2, which is not affected by the absence of *Jnk3*. In contrast, ERK1/2 activation is abolished in *Jnk3^o/o^* mice 3 h after KA treatment ([@B19]). Thus it is reasonable to consider that changes in p-ERK1/2 in *Prnp^o/o^Jnk3^o/o^* mice after KA treatment are mainly associated with the *Prnp^o/o^* background. p-ERK1/2 is expressed by mossy fibers of granule cells, as well as by reactive, GFAP-positive astrocytes, after KA treatment; in contrast, JNK activation mainly takes place in dying neurons (CA1--CA3 pyramidal neurons; [@B49]). Our histological and biochemical analyses demonstrate that an increased number of GFAP-positive cells can be seen in the double-knockout hippocampus without relevant cell death. These data also contrast with those obtained with *Jnk3^o/o^* mice ([@B76]; [@B19]). Although we cannot rule out an effect of activated p-ERK1/2/GFAP--positive astrocytes on JNK-activated dying neurons, it seems that intrinsic ERK1/2 phosphorylation (which is not blocked by deletion of *Jnk3*) in granule cells could participate in the sustained *c-jun* overexpression in response to KA in a *Prnp^o/o^* background. On the other hand, *c-jun* was upregulated in *Prnp^o/o^Jnk3^o/o^* mice after KA treatment, but no neurodegeneration was observed when compared with both *Prnp^+/+^Jnk3^+/+^* and *Prnp^o/o^Jnk3^+/+^* mice in brain sections when examined by different methods (Fluoro-Jade B or TUNEL). Thus c-Jun overexpression cannot be associated with cell death and needs to be phosphorylated by JNK3 to induce cell death. Indeed, JNK3 phosphorylates c-Jun at Ser-63 and Ser-73, and abrogation of c-Jun phosphorylation using alanine mutants for c-Jun at Ser-63 and Ser-73 confers resistance to epileptic seizures and neuronal apoptosis induced by KA ([@B6]). On the other hand, *c-fos* was upregulated only in dying *Prnp^o/o^Jnk3^+/+^* cells, and *Jnk3* deletion did not totally decrease *c-fos* levels, suggesting its implication in different KA-signaling mechanisms. In addition, our data also implicate p53 in these results since phosphorylation of p53 follows the activity pattern of JNK3 (only activated in *Prnp^o/o^Jnk3^+/+^* after KA treatment). This is compatible with the recent proposal that p53 activation after glutamatergic stimulus depends on JNK activity ([@B18]).

JNK3-mediated signaling activates the AP-1 complex, which triggers the expression of early response genes such as *c-fos* or *c-jun*, as well as the up-regulation of *cox-2*, which is involved in the inflammatory response after KA treatment ([@B66]). In fact, pharmacological inhibition or genetic deletion of *cox-2*, but not Cox-1, increases susceptibility to KA-induced hippocampal excitotoxicity ([@B65]). In our study, *cox-2* was up-regulated after KA treatment in *Prnp^o/o^Jnk3^+/+^,* whereas in *Prnp^o/o^Jnk3^o/o^*, *cox-2* expression was largely reduced (up to 60%), indicating a reduction in inflammatory responses in the double-knockout mice. Indeed, a direct relation between JNK activity, c-Jun phosphorylation, and *cox-2* up-regulation has been demonstrated in several models ([@B69]), and the up-regulation of Cox-2 mediated by JNK is necessary and required for neurodegeneration in a mouse model of Parkinson disease ([@B28]).

A putative role of PrP^C^ at the neuronal membrane as modulator of GluR6/7--mediated neurotransmission and JNK3 activity
------------------------------------------------------------------------------------------------------------------------

GluR6 knockout and *Jnk3^o/o^* mice are resistant to KA treatment. In fact, it has been reported that GluR6 binds to PSD-95, and this binding is necessary to trigger GluR6-dependent neurotransmission ([@B54]) due to the formation of a stable trimeric complex GluR6--PSD-95--MLK3 ([@B34]). In this study we found large colocalization of PrP^C^ with GluR6/7 in the PSD. Moreover, *Prnp* deletion favors the interaction between PSD-95 and GluR6/7 in the presence of KA. Taken together, our results suggest that absence of PrP^C^ enhances the interaction of the ternary complex PSD-95 and GluR6 and most probably MLK3 at the synapse, thus enabling GluR6-mediated intracellular signaling. This in turn leads to JNK3 activation among that of other kinases.

As mentioned, PrP^C^ has been detected in axon and synaptic contacts, although whether its location is presynaptic or postsynaptic is not fully determined ([@B23]; [@B22]). Here we report that a fraction of PrP^C^ localized to the PSD, where neurotransmitter receptors are located. Recent studies indicate that PrP^C^ is a constitutive basal protector against NMDA-mediated toxicity. Deletion of the *Prnp* gene induces enhanced prolonged NMDA-evoked currents in hippocampal neurons, which increases neuronal excitability and glutamate excitotoxicity ([@B29]). The same authors described changes in some parameters associated with AMPA/KA--mediated miniature inhibitory postsynaptic currents and γ-aminobutyric acid A--mediated miniature inhibitory postsynaptic currents ([@B29]). These findings are in concordance with our data ([@B49], [@B50]), which demonstrated that enhanced neurotoxicity to KA in hippocampal slices of *Prnp^o^*^/*o*^ mice has both a KA receptor and a NMDA receptor component. However, the molecular mechanism by which PrP^C^ inhibits NMDA and KA receptors is unclear. PrP^C^ may either influence agonist binding, favor the closed state of the channel, or interfere with the signal transmission, thus forming a negative modulator complex ([@B58]). In any case PrP^C^ expression does not appear to be critical for neuronal glutamate transport ([@B63]). Irrespective of the molecular mechanisms responsible for these effects, our data indicate that PrP^C^ (both for KA and NMDA receptors) inhibits glutamatergic neurotransmission and that the absence of PrP^C^ enhances neurotoxic signaling. Furthermore, it is tempting to speculate on a similar protective effect in other brain injuries that share a similar activation mechanism through the receptor complex GluR6/7--PSD-95--MLK3, where signaling is transmitted downstream into the JNK3 pathway. Further studies would be needed to confirm this hypothesis. In this regard, increased levels of PrP^C^ in plasma have been found after acute ischemia in rats and in human stroke patients ([@B40]). Indeed, [@B71]) suggested that the extent of the up-regulation of PrP^C^ in ischemic brains depends on the severity of ischemia and may therefore reflect the extent of ischemia-induced neuronal damage. We believe that discerning the functional roles of PrP^C^ at the synapse, as well as its specific interacting partners in normal and pathological conditions at the synapse, would help us to understand neurotoxicity in synapse-associated neurodegenerative diseases and ischemic processes. [Figure 8](#F8){ref-type="fig"} shows a general scheme depicting the role of the GluR6/7--JNK3 signaling pathway in mediating the neurotoxic effects of KA in mouse hippocampus in the absence of PrP^C^.

![Proposed scheme illustrating the neurotoxic effects of KA in mouse hippocampus in the absence of PrP^C^. In the absence of *Prnp* (knockout, siRNA), KA activates neurotoxic signaling in the hippocampal cells, favoring the interaction of PSD-95 with GluR6/7, inducing c-Jun and c-Fos overexpression and JNK3 activation, which, in turn, provokes the phosphorylation of c-Jun, leading to neurotoxicity and cell death.](3041fig8){#F8}

MATERIALS AND METHODS
=====================

Animals
-------

*Prnp* knockout mice Zürich I (*Prnp^o/o^*) were purchased from the European Mouse Mutant Archive (EMMA, Monterotondo, Italy). *Prnp^o/o^* mice were backcrossed with C57BL6J mice from 10 generations up to obtain 92--95% of C57BL6J microsatellite markers (Charles River background analysis) from the previous 46--48% of the Zürich I mice. *Jnk3* knockout mice were generated as described elsewhere ([@B76]). Double-knockout animals (*Prnp^o/o^Jnk3^o/o^*) were generated by crossing backcrossed *Prnp^o/o^* mice with *Jnk3^o/o^* mice (with 70--75% of C57BL6J microsatellite markers). To avoid putative background-specific differences between mice, all of the experiments were conducted using littermates derived from heterozygous (*Prnp^+/o^Jnk3^+/o^*) parents. Specific primers for *Prnp* genotyping were designed in our laboratory based on the original P10 and P3 primers described elsewhere ([@B13]). The *Jnk3* knockout mice were genotyped as described elsewhere ([@B30]). A total of 45 litters were used in the present study. All experimental procedures were carried out in accordance with the guidelines of the Spanish Ministry of Science and Technology following European standards.

Reagents and antibodies
-----------------------

KA, PI, SP600125, TAT-JIP peptide, DNQX, NS-102, and antitubulin antibody were from Sigma (Poole, United Kingdom). Anti--p-ERK1/2, total anti--ERK1/2, p-c-Jun (Ser-63), anti--p-JNK, anti--p-p53 (Ser-15). and total anti-JNK3 antibodies were from Cell Signaling (Beverly, MA). Anti--c-Jun antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti--c-Fos was from Calbiochem (Darmstadt, Germany). Postsynaptic density 95 (anti--PSD-95) and glutamate receptor 6/7 (anti--GluR6/7) antibodies and Fluoro-Jade B were from Millipore (Billerica, MA). SAF61 antibody was from Spi-Bio (Cayman Chemical, Massy, France), and 6H4 antibody was from Prionics (Schlieren, Switzerland). SYBR green was from Roche (Basel, Switzerland).

KA injections
-------------

To induce convulsive nonlethal seizures in mice, we developed a progressive KA treatment by administering several consecutive intraperitoneal (i.p.) injections of the glutamate agonist KA dissolved in 0.1 M PBS, pH 7.2 ([@B49]). PBS 0.1 M, pH 7.2 (vehicle), was injected as control. Adult animals (*Prnp^o/o^Jnk3^+/+^*; 2--3 mo old) were weighed and i.p. injected with two injections of KA (6 mg/kg body weight) at time 0 and 30 min. Seizure intensity after KA injections was evaluated as described previously during the 4 h after the first KA injection ([@B46]; [@B33]). Tissue samples were analyzed at the indicated times.

Immunohistochemistry
--------------------

After KA treatment, mice were perfused with phosphate buffered 4% paraformaldehyde, pH 7.3, postfixed overnight in the same fixative, and cryoprotected in 30% sucrose. Coronal sections (30 μm thick) were obtained in a freezing microtome (Leica, Wetzlar, Germany). Free-floating sections were rinsed in 0.1 M PBS, and endogenous peroxidases were blocked with 3% H~2~O~2~ and 10% methanol dissolved in 0.1 M PBS. After extensive rinsing, sections were incubated in 0.1 M PBS containing 0.2% gelatin, 10% normal serum, 0.2% glycine, and 0.2% Triton X-100 for 1 h at room temperature. Sections were then incubated overnight at 4°C with the distinct primary p-ERK1/2 and GFAP antibodies. After washing in 0.1 M PBS containing 0.2% Triton X-100, sections were incubated with Alexa Fluor 488-- and/or Alexa Fluor 568--tagged secondary antibodies (1:200 diluted; Molecular Probes, Eugene, OR), washed in 0.1 M, PBS counterstained with 4′,6-diamidino-2-phenylindole (DAPI; 1 μM in 0.1 M PBS; 10 min), and mounted in Fluoromount (Vector Labs, Burlingame, CA). Dying cells in histological sections were measured using the S7100 ApopTag peroxidase in situ apoptosis (TUNEL) detection kit, following the manufacturer\'s instructions (Chemicon, Temecula, CA).

Fluoro-Jade B staining of dying neurons in brain sections
---------------------------------------------------------

Coronal brain sections were obtained as described and rinsed for 2 h in 0.1 M Tris, pH 7.4, mounted, and air dried at room temperature overnight. The next day, sections were pretreated for 3 min in absolute ethanol, followed by 1 min in 70% ethanol and 1 min in distilled water. They were then oxidized in a solution of 0.06% KMnO~4~ for 15 min. After three rinses of 1 min each in distilled water, the sections were incubated for 30 min in a solution of 0.001% Fluoro-Jade B (Chemicon) containing 0.01% of DAPI (Sigma) in 0.1% acetic acid. The slides were rinsed in deionized water for 3 min each, dried overnight, cleared in xylene, and cover-slipped with Eukitt (Merck, Darmstadt, Germany) and examined using an Olympus (Hamburg, Germany) BX61 epifluorescence microscope.

Neuronal primary cultures and treatments
----------------------------------------

Primary hippocampal neurons were prepared from the hippocampus of perinatal (embryological day 18 to day of birth) animals. Briefly, hippocampal neurons were grown on dishes coated with poly-[d]{.smallcaps}-lysine (30 μg/ml) in Neurobasal medium supplemented with B27, 0.5 mM glutamine, 12.5 mM glutamate, and antibiotics (all purchased from Invitrogen, Carlsbad, CA). At 9 d in vitro (DIV), hippocampal neurons were infected with lentivirus carrying the eGFP construct ([@B42]) or the siRNA for *Prnp*. Lentiviral particles were produced by transient transfection of 293FT cells with Lipofectamine 2000 (Invitrogen), using Mission short hairpin RNA prion protein NM_011170 (Sigma), the second-generation packaging construct psPAX2 (Tronolab, Lausanne, Switzerland), and the envelope plasmid pMD2G (Tronolab). 293FT cells were cultured in DMEM supplemented with 10% fetal calf serum and without antibiotics before transfection. Medium was changed and supplemented with antibiotics after 6 h. Vector supernatants containing viral particles were harvested ∼24 and 48 h later and concentrated by ultracentrifugation (2 h at 26,000 × *g* at 4°C). After 5 d of infection, cultured neurons were treated with KA (150 μM dissolved in 0.1 M PBS; for 8 h). After treatment, cultures were rinsed twice in KA-free culture medium. The next day, cultures were incubated for 2 h with WST-1 reagent (Roche), and the absorbance (450 nm) was measured in a multiwell plate reader (Merck ELISA System MIOS).

Organotypic slice cultures of hippocampus
-----------------------------------------

Hippocampal slice cultures were prepared from day of birth as described elsewhere ([@B61], [@B62]; [@B20]). Animals were anaesthetized, and brains were removed aseptically from the skull. Horizontal slices (325--350 μm thick) of the hippocampus were obtained using a McIlwain tissue chopper (Mickle Laboratory, Guildford, United Kingdom). Sections were maintained and selected in cold MEM supplemented with glutamine (2 mM; MEM dissecting salt solution) for 45 min. Selected slices were then cultured using the membrane interface method ([@B61]). Slices were placed on 30-mm-diameter sterile membranes (Millicell-CM, Millipore) and transferred to six-well tissue culture plates (Nunc, Roskilde, Denmark). Cultures were incubated with 1.2 ml of culture medium (50% MEM, 25% horse serum, 25% Hank\'s buffered salt solution, containing 2 mM glutamine and 0.04% NaHCO~3~, adjusted to pH 7.3). The membrane cultures were maintained in a humidified incubator at 37ºC in a 5% CO~2~ atmosphere. The medium was changed every 2 d. All culture reagents were purchased from Invitrogen-Life Technologies (Merelbeke, Belgium).

Neuronal death after treatments in organotypic slice cultures was monitored by PI uptake ([@B49]). After 9 d of culture, hippocampal slice cultures were serum deprived for 3 h, and 150 μM of KA was added. Cultured were exposed to protein JNK inhibitors (SP600125 20 μM or TAT-JIP 10 μM) for 45 min before KA treatment. After treatment, slices were rinsed twice in KA-free culture medium. The next day, slices were incubated for 2 h with 1 μg/ml of PI dissolved in culture medium. PI-treated slices were fixed for 1 h with 4% buffered paraformaldehyde, pH 7.2. After rinsing, cultures were mounted in Fluoromount and photodocumented in an Olympus confocal microscope. To determine the maximum PI fluorescence for quantification, total fluorescence in the pyramidal layer of the hippocampus was measured in a 500-μm segment of the layer in the CA1--CA3 regions after incubation with 10 mM glutamate for 10 min, using Quantity One Imaging and Analysis software (Bio-Rad Laboratories, Hemel Hempstead, United Kingdom).

PSD purification from mice hippocampus
--------------------------------------

The PSD fraction was purified from adult mice (10--12 mo old) as indicated ([@B14]). Briefly, tissue was weighed, and 1 ml of homogenization buffer (0.32 M sucrose, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid \[HEPES\], pH 7.4, 2 mM EDTA, 2.5 mM *N*-ethylmaleimide, containing protease and phosphatase inhibitors) was added for every 125 mg of tissue. Samples were homogenized in a glass--Teflon Dounce homogenizer (40 strokes) and centrifuged at 800 × *g* for 10 min at 4°C. The supernatant was centrifuged at 10,000 × *g* for 15 min at 4°C, and pellet was resuspended in 0.5 ml of Triton buffer: 50 mM HEPES, pH 7.4, 2 mM EDTA, 5 mM EGTA, 1% Triton X-100, 2.5 mM *N*-ethylmaleimide, containing protease and phosphatase inhibitors) for every 125 mg of tissue. Samples were centrifuged at 50,000 × *g* for 30 min at 4°C, and the pellet was resuspended in 125 μl of resuspension buffer---50 mM Tris, pH 7.4, 1% SDS (when used for Western blotting) or 50 mM Tris, pH 8.5, 1% deoxycholate (when used for immunoprecipitation experiments)---for every 125 μg of tissue. Samples were incubated for 10 min at room temperature and centrifuged at 50,000 × *g* for 15 min at 4°C.

Western blotting
----------------

Tissue samples from the hippocampus of KA-treated or vehicle-treated mice were homogenized (10% wt/vol) in ice-cold lysis buffer---50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% (wt/vol) Triton X-100, 0.5% (wt/vol) Nonidet P-40 (IGEPAL; Sigma), glycerol 10%, 1 mM EDTA, 1 mM EGTA, and protease and phosphatase inhibitors---using a motor-driven, glass--Teflon homogenizer in ice and centrifuged at 15,000 × *g* for 20 min. After protein quantification, tissue extracts were boiled in Laemmli sample buffer at 100ºC for 5 min, followed by 6--10% SDS--PAGE electrophoresis, electrotransferred to polyvinylidene fluoride (PVDF) membranes (Millipore), and processed for immunoblotting and the ECL Plus kit (Amersham-Pharmacia Biotech, GE Healthcare Bio-Sciences, Piscataway, NJ).

Immunoprecipitation
-------------------

Cell extracts from total hippocampus or hippocampal PSD fractions were used for immunoprecipitation experiments. For total hippocampus, cell extracts were processed as indicated for Western blot. After protein quantification, 1 mg of hippocampal protein extract was mixed with 10 μl of protein A/G--Sepharose (Sigma) previously equilibrated with lysis buffer---50 mM Tris--HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl~2~, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and protease and phosphatase inhibitors---for 2 h (preclearing). Samples were centrifuged, and the supernatant was mixed with the indicated immunoprecipitation antibodies plus 10 μl of protein A/G--Sepharose overnight at 4°C. The immunocomplexes were washed in lysis buffer and once in lysis buffer plus 0.25 M NaCl. For immunoprecipitation from PSD hippocampal fractions, PSD fractions were diluted with RIPA buffer: 150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0, up to 500 μl. Samples were processed as described earlier but using RIPA buffer instead of lysis buffer for immunoprecipitation washes. Proteins attached to Sepharose beads were eluted with SDS--PAGE sample buffer, subjected to SDS--PAGE, transferred to PVDF membranes, and probed with the GluR6/7 and PSD-95 antibodies.

RT-qPCR
-------

RT-qPCR was performed on total RNA extracted with the mirVana isolation kit (Ambion, Austin, TX) from the hippocampus of analyzed mice. Purified RNAs were used to generate the corresponding cDNAs, which served as PCR templates for mRNA quantification. The primers used in this study for RT-qPCR validation are given in Supplemental Figure S1. PCR amplification and detection were performed with the Roche LightCycler 480 detector, using 2x SYBR Green Master Mix (Roche) as reagent, following the manufacturer\'s instructions. The reaction profile was as follows: denaturation--activation cycle (95°C for 10 min) followed by 40 cycles of denaturation--annealing--extension (95°C, 10 min; 72°C, 1 min; 98°C, continuous). mRNA levels were calculated using the LightCycler 480 software. The data were analyzed using the ΔΔ*C*t method, which provides the target gene expression values as fold changes in the problem sample compared with a calibrator sample. Both problem and calibrator samples were normalized by the relative expression of a housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase \[GAPDH\]).

Statistical analysis
--------------------

All data are presented as mean ± SEM. Pairwise one-way analysis of variance (ANOVA) with Newman--Keuls multiple comparisons test was used for comparison. The operations were performed using Systat Software (Chicago, IL) or Statgraphics (StatPoint Technologies, Warrenton, VA). Statistical significance was set at \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001.
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:   c-Jun N-terminal kinase 3
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